Real-World Data on Treatment Management and Outcomes of Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer in Greece (The EpOCa Study)
New treatment modalities have been recently introduced in the management of ovarian cancer (OC). Herein, we sought to investigate their implementation in routine clinical practice and examine the real-world management of OC in Greece. EpOCa was a non-interventional, multicenter, retrospective study in patients with advanced epithelial OC. The primary outcome was to estimate the proportions of the different treatment regimens used per line of therapy, while progression-free survival (PFS) and overall survival (OS) were the key secondary endpoints. A total of 154 patients were enrolled in the study, among whom, 40% were tested for BRCA mutations and 30% were found to be positive. Nearly 90% of patients underwent debulking surgery at diagnosis, with few operations being also recorded upon relapse. Platinum-based chemotherapy (CT) was predominantly used in the first line with half of patients also receiving angiogenesis inhibitor (AI), while non-platinum-based CT was preferred in later lines. The median PFS was 18.2 and 8.8 months in the first- and second-line setting, respectively, whereas the median OS was approximately 50 months. Our study adds to the available, but limited, real world data on the management of ovarian cancer providing evidence regarding the applied treatment strategies and outcomes of patients in Greece.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Current oncology (Toronto, Ont.) - 28(2021), 6 vom: 10. Dez., Seite 5266-5277 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liontos, Michalis [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Advanced ovarian cancer |
|---|
| Anmerkungen: |
Date Completed 24.03.2022 Date Revised 24.03.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/curroncol28060440 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334760127 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334760127 | ||
| 003 | DE-627 | ||
| 005 | 20231225224408.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/curroncol28060440 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1115.xml |
| 035 | |a (DE-627)NLM334760127 | ||
| 035 | |a (NLM)34940079 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liontos, Michalis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-World Data on Treatment Management and Outcomes of Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer in Greece (The EpOCa Study) |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.03.2022 | ||
| 500 | |a Date Revised 24.03.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a New treatment modalities have been recently introduced in the management of ovarian cancer (OC). Herein, we sought to investigate their implementation in routine clinical practice and examine the real-world management of OC in Greece. EpOCa was a non-interventional, multicenter, retrospective study in patients with advanced epithelial OC. The primary outcome was to estimate the proportions of the different treatment regimens used per line of therapy, while progression-free survival (PFS) and overall survival (OS) were the key secondary endpoints. A total of 154 patients were enrolled in the study, among whom, 40% were tested for BRCA mutations and 30% were found to be positive. Nearly 90% of patients underwent debulking surgery at diagnosis, with few operations being also recorded upon relapse. Platinum-based chemotherapy (CT) was predominantly used in the first line with half of patients also receiving angiogenesis inhibitor (AI), while non-platinum-based CT was preferred in later lines. The median PFS was 18.2 and 8.8 months in the first- and second-line setting, respectively, whereas the median OS was approximately 50 months. Our study adds to the available, but limited, real world data on the management of ovarian cancer providing evidence regarding the applied treatment strategies and outcomes of patients in Greece | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a advanced ovarian cancer | |
| 650 | 4 | |a management strategy | |
| 650 | 4 | |a real world data | |
| 650 | 4 | |a treatment sequence | |
| 700 | 1 | |a Timotheadou, Eleni |e verfasserin |4 aut | |
| 700 | 1 | |a Papadopoulos, Emmanuel I |e verfasserin |4 aut | |
| 700 | 1 | |a Zafeiriou, Zafeiris |e verfasserin |4 aut | |
| 700 | 1 | |a Lampropoulou, Dimitra Ioanna |e verfasserin |4 aut | |
| 700 | 1 | |a Aravantinos, Gerasimos |e verfasserin |4 aut | |
| 700 | 1 | |a Mavroudis, Dimitrios |e verfasserin |4 aut | |
| 700 | 1 | |a Christodoulou, Christos |e verfasserin |4 aut | |
| 700 | 1 | |a Nikolaidi, Adamantia |e verfasserin |4 aut | |
| 700 | 1 | |a Somarakis, Alvertos |e verfasserin |4 aut | |
| 700 | 1 | |a Papadimitriou, Christos |e verfasserin |4 aut | |
| 700 | 1 | |a Papandreou, Christos |e verfasserin |4 aut | |
| 700 | 1 | |a Bamias, Aristotelis |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current oncology (Toronto, Ont.) |d 1998 |g 28(2021), 6 vom: 10. Dez., Seite 5266-5277 |w (DE-627)NLM09444482X |x 1718-7729 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2021 |g number:6 |g day:10 |g month:12 |g pages:5266-5277 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/curroncol28060440 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2021 |e 6 |b 10 |c 12 |h 5266-5277 | ||